Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 246

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 246
---
 potential to be adversely impacted. The material weakness resulted from ineffective risk assessment related to the invoicing IT environment, which lead to a
lack of the required number of trained IT personnel with the appropriate skills and knowledge related to the design, implementation and operating effectiveness of internal control, and ineffective control activities related primarily to the
implementation of the new invoicing systems.”

Enfusion

The consolidated financial statements of Enfusion, Inc. appearing in Enfusion, Inc.’s Annual Report (Form
10-K) for the year ended December 31, 2023, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and
incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

175

ENFUSION STOCKHOLDER PROPOSALS

If the Merger Agreement is adopted and the Transactions are completed, Enfusion will become a wholly owned subsidiary of Clearwater or be
merged into Acquirer, and, consequently, there will be no annual meeting of Enfusion Stockholders in 2025 or thereafter. If the Merger Agreement is not adopted or the Transactions are not completed for any reason, Enfusion will hold an annual
meeting of its stockholders in 2025.

To be eligible for inclusion in Enfusion’s proxy statement for the 2025 annual meeting of
stockholders, stockholder proposals must have been received at Enfusion’s principal executive offices no later than December 27, 2024. Any stockholder who wishes to bring a proposal or nominate a person for election to the Enfusion Board
at the 2025 annual meeting must provide written notice of the proposal or nomination to the attention of Enfusion’s Legal Department no earlier than the close of business on February 13, 2025 nor later than the close of business on
March 15, 2025. In addition to satisfying the foregoing requirements under the Enfusion Bylaws, to comply with the universal proxy rules under the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other
than Enfusion’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act within the time period specified above. Stockholder proposals should be
addressed to: Enfusion, Inc., Attention: Legal Department, 125 South Clark Street, Suite 750, Chicago, IL